

## Neffy<sup>®</sup> (epinephrine nasal spray)

Policy # 00908

Original Effective Date: 01/01/2025

Current Effective Date: 01/01/2026

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

### When Services May Be Eligible for Coverage

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member’s contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider Neffy<sup>®‡</sup> (epinephrine nasal spray) to be **eligible for coverage\*\*** when the patient selection criteria are met.

#### Patient Selection Criteria

Coverage eligibility for Neffy (epinephrine nasal spray) will be considered when the following criteria are met:

- Patient weighs 15 kg or more; AND
- There is clinical evidence or patient history that suggests the use of GENERIC versions of the EpiPen<sup>®‡</sup> (epinephrine auto-injector) products will be ineffective or cause an adverse reaction to the patient.

*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary\*\* if not met).*

### When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Neffy (epinephrine nasal spray) WITHOUT clinical evidence or patient history that suggests the use of GENERIC versions of the EpiPen (epinephrine auto-injector) products will be ineffective or cause an adverse reaction to the patient to be **not medically necessary.\*\***

### When Services Are Considered Investigational

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

Based on review of available data, the Company considers the use of Neffy (epinephrine nasal spray) when the patient selection criteria are not met (EXCEPT that denoted as **not medically necessary\*\***) to be **investigational.\***

Neffy® (epinephrine nasal spray)

Policy # 00908

Original Effective Date: 01/01/2025

Current Effective Date: 01/01/2026

## **Background/Overview**

Neffy is an alpha and beta-adrenergic receptor agonist indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients 4 years of age and older who weigh 15 kg or greater. The recommended dose of Neffy for patients 30 kg or more is one spray administered into one nostril, which delivers a total dose of 2 mg of epinephrine. The recommended dose of Neffy for patients 15 kg to less than 30 kg is one spray of Neffy 1 mg into one nostril. A second dose may be administered if needed after 5 minutes. Caution must be taken during administration as Neffy should be sprayed directly into the nostril and not the inside septum or outer wall of the nose so as not to lose medication. It should be noted that there are several epinephrine products on the market, including the generic equivalents of the EpiPen line of products. The previously mentioned products offer prices that are substantially more economical than Neffy's price. There is no clinical advantage of using Neffy over the generic equivalents of the EpiPen line of products.

## **FDA or Other Governmental Regulatory Approval**

### **U.S. Food and Drug Administration (FDA)**

Neffy is approved for emergency treatment on type I allergic reactions, including anaphylaxis, in adult and pediatric patients 4 years of age and older who weigh 15 kg or greater.

## **Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

The patient selection criteria presented in this policy take into consideration clinical evidence or patient history that suggests the use of the GENERIC versions of the EpiPen (epinephrine auto-injector) line of products will be ineffective or cause an adverse reaction to the patient. Based on a review of the data, in the absence of the above mentioned caveat, there is no advantage of using Neffy (epinephrine nasal spray) over the generic equivalents of the EpiPen (epinephrine auto-injector) line of products.

## **References**

1. Neffy [package insert]. ARS Pharmaceutical Operations, Inc. San Diego, California. Updated October 2025.

## **Policy History**

Original Effective Date: 01/01/2025

Current Effective Date: 01/01/2026

12/05/2024 Medical Policy Committee review

Neffy® (epinephrine nasal spray)

Policy # 00908

Original Effective Date: 01/01/2025

Current Effective Date: 01/01/2026

12/11/2024 Medical Policy Implementation Committee approval. New policy.

12/04/2025 Medical Policy Committee review

12/10/2025 Medical Policy Implementation Committee approval. Updated weight requirement from 30 kg to 15 kg to reflect update in the FDA labeling.

Next Scheduled Review Date: 12/2026

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
  1. Consultation with technology evaluation center(s);
  2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
  3. Reference to federal regulations.

\*\*Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

Nefly® (epinephrine nasal spray)

Policy # 00908

Original Effective Date: 01/01/2025

Current Effective Date: 01/01/2026

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

**NOTICE:** Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.